bullish
Strategic Reviews, Liquidations, and Buybacks: Key Financial Developments in Biopharma, Real Estate
2 Views08 Dec 2024 20:00
Kronos Bio (KRON) undergoes strategic review with 83% workforce reduction and CEO resignation, trading below net cash value.
What is covered in the Full Insight:
- Introduction to Key Financial Developments
- Portfolio Idea: Kronos Bio (KRON)
- Quick Pitch: Equity Commonwealth (EQC)
- Portfolio Idea Updates: Marlowe (MRL:L)
- Quick Pitch Updates and Other Insights
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Special Situation Investments
Event-Driven Investment Opportunities
Price Chart(Sign Up to Access)
- Loading...
x